Showing results (111-120 of 129) with videos related to
Sort By:
Pageof 13
Journal of Cardiac Failure|April 4, 2016
Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary SpecialtyDaniel J Lenihan, Gregory Hartlage, Jeanne DeCara, et al.JACC. Cardiooncology|April 17, 2025
Quality-of-Care Measures for Cardio-Oncology: An IC-OS and ACC Cardio-Oncology Leadership Council PerspectiveVijay U Rao, Anita Deswal, Daniel Lenihan, et al.Journal of the National Cancer Institute|November 12, 2020
Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging CouncilsLauren A Baldassarre, Eric H Yang, Richard K Cheng, et al.Cancer Medicine|March 27, 2026
Standardizing the Clinical Approach to Cancer Therapy-Related Cardiac Dysfunction: Applying Cardio-Oncology Guidelines as a Practical Tool for Hematology and Oncology ProvidersAbdelrahman Ali, Suparna C Clasen, Anne Blaes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2021
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-UpMartine Piccart, Marion Procter, Debora Fumagalli, et al.The Canadian Journal of Cardiology|June 26, 2016
Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer TherapySean A Virani, Susan Dent, Christine Brezden-Masley, et al.European Heart Journal|December 14, 2021
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statementJoerg Herrmann, Daniel Lenihan, Saro Armenian, et al.JAMA Oncology|November 13, 2025
Immune Checkpoint Inhibitor-Associated Cardiovascular Toxic Effects: International Cardio-Oncology Society Position StatementJoerg Herrmann, Ana Barac, Joseph Carver, et al.BMJ (Clinical Research Ed.)|December 9, 2021
Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trialMonika K Krzyzanowska, Jim A Julian, Chu-Shu Gu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2015
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31Karen A Gelmon, Frances M Boyle, Bella Kaufman, et al.Pageof 13